Loading...
•
Jun 30, 2021
Vanda Q2 2021 Earnings Report
Reported a 9% increase in total revenues compared to Q2 2020.
Key Takeaways
Vanda Pharmaceuticals reported Q2 2021 total revenues of $67.9 million, a 9% increase compared to Q2 2020. The company's income before taxes was $12.6 million, compared to $11.1 million in the second quarter of 2020.
Total revenues for Q2 2021 were $67.9 million, a 9% increase compared to Q2 2020.
HETLIOZ® net product sales were $44.5 million in Q2 2021, a 7% increase compared to Q2 2020.
Fanapt® net product sales were $23.4 million in Q2 2021, a 13% increase compared to Q2 2020.
Income before taxes was $12.6 million in Q2 2021 compared to $11.1 million in Q2 2020.
Revenue by Segment
Forward Guidance
Vanda expects to achieve the following financial objectives in 2021:
Positive Outlook
- Total revenues between $270 to $300 million
- HETLIOZ® net product sales between $180 to $200 million
- Fanapt® net product sales between $90 to $100 million
- Year-end 2021 Cash greater than $400 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...